USPTO Examiner SCHLIENTZ NATHAN W - Art Unit 1616

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18967337PLANT DERIVED FOOD PRESERVATIVEDecember 2024July 2025Allow711YesNo
18962472Herbicidal compositions comprising glufosinateNovember 2024September 2025Allow1020YesNo
18947430SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONSNovember 2024April 2025Allow510YesNo
18909414POLYMERIC ANTI-MICROBIAL FILMOctober 2024December 2024Allow200NoNo
18749727GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERYJune 2024August 2025Abandon1410NoNo
18737301THIOPHENE ACETIC ACID FOR PLANT GROWTH REGULATIONJune 2024March 2025Abandon910NoNo
18425739Sustained Release Compositions Comprising Micronized TolcaponeJanuary 2024September 2024Allow800NoNo
18293034AGRICULTURAL APPLICATIONS OF FATTY ACID REACTION PRODUCTS OF DEXTRINS OR DEXTRANJanuary 2024September 2025Allow2020NoNo
18490070ANTIMICROBIAL AGENT FOR COATING COMPOSITIONOctober 2023January 2026Allow2730YesNo
18376765APPLICATION OF STRUCTURALLY ALTERED GAS MOLECULES TO ENHANCE PRODUCTION OF ADENOSINE TRIPHOSPHATE IN LIVING ORGANISMS WITH NO INCREASE IN REACTIVE OXYGEN SPECIESOctober 2023March 2024Allow511YesNo
18238934Thiophene Acetic Acid for Plant Growth RegulationAugust 2023March 2024Allow610YesNo
18238883COMPOSITION FOR GENERATION OF CHLORINE DIOXIDE FOR USE AS SANITIZERAugust 2023March 2026Abandon3110NoNo
18237978NANOCRYSTALLINE TIO2 AND ZNO ORGANOSELENIUM SCAFFOLDS POSSESING DISELENIDE (SE-SE) FUNCTIONALITY FOR BIOMEDICAL TECHNOLOGYAugust 2023August 2025Abandon2440NoNo
18231449GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERYAugust 2023March 2024Allow720YesNo
18359099METHODS FOR THE CONTROL OF ARTHROPODS USING NEAR-IDEAL GAS PHASE HYDROGEN PEROXIDEJuly 2023December 2024Allow1610YesNo
18359316PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITYJuly 2023February 2024Allow700YesNo
18225852SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONSJuly 2023September 2024Abandon1310YesNo
18218502Purified and Enhanced Hydrogen Peroxide Disinfecting Solution for the Rapid Inactivation of COVID-19 and Other PathogensJuly 2023March 2026Abandon3210NoNo
18333891PATHOGENIC CONTROL COMPOSITIONS AND METHODSJune 2023January 2026Abandon3110NoNo
18206647ANTIMICROBIAL COMPOSITIONJune 2023March 2026Abandon3310NoNo
18034477HYGROSCOPIC SALT MICROENCAPSULATION, AND USES THEREOFApril 2023February 2026Allow3410NoNo
18140395HERBICIDAL PHENYLETHERSApril 2023July 2024Allow1410NoNo
18131081FORMABLE AQUATIC COVERINGS FOR PREVENTING BIOFOULINGApril 2023March 2025Allow2310NoNo
18108803SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONSFebruary 2023July 2023Allow500YesNo
18167124ANTIMICROBIAL COMPOSITIONSFebruary 2023March 2024Allow1320YesNo
18100177HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDESJanuary 2023June 2024Abandon1701NoNo
18097704COMPOSITIONS COMPRISING ETHOXYLATED LECITHIN AND METHODS OF MAKING AND USING THE SAMEJanuary 2023May 2024Allow1610YesNo
18090884MAGNETIC INORGANIC IRON-BASED NANOPARTICLESDecember 2022December 2024Allow2420NoNo
18088083FUNGICIDAL COMBINATIONSDecember 2022March 2025Allow2730YesNo
17927867PREPARATION METHOD FOR L-GLUFOSINATE-AMMONIUM POWDERNovember 2022July 2025Allow3200YesNo
17973359METHODS FOR MANAGING HERBICIDE VAPORIZATIONOctober 2022May 2025Abandon3130NoNo
17970184Use of Erythritol Compositions As Mammal-Safe InsecticidesOctober 2022April 2024Allow1710YesNo
17907201ANTIMICROBIAL FORMULATION COMPRISING METAL NANOPARTICLES OR NANOPARTICLES OF METAL OXIDES SYNTHESISED FROM PLANT EXTRACTSSeptember 2022January 2026Abandon4010NoNo
17949299Application of Nanosulfur in Tomato Fusarium Wilt ControlSeptember 2022December 2023Abandon1520NoNo
17910195PROTECTIVE ANTIMICROBIAL SYSTEMSeptember 2022April 2025Allow3110YesNo
17798755COMPOSITIONS COMPRISING ALPHA, BETA-UNSATURATED ALDEHYDE AND METHODS OF USING SAMEAugust 2022December 2025Abandon4010NoNo
177965923-ALKOXYBENZAMIDE DERIVATIVE, AND PEST CONTROL AGENTJuly 2022March 2026Allow4461YesNo
17759390METHODS OF USING A COLLOIDAL SILVER-BASED COMPOSITION IN REDUCING OR PREVENTING MICROBIAL CONTAMINATION IN PLANTS OR EXPLANTS IN TISSUE CULTURE PROCESSESJuly 2022October 2025Allow3910YesNo
17852788METHOD OF PROMOTING PLANT GROWTH EFFECTSJune 2022April 2024Allow2220NoNo
17848726BIO-LIGHT ELEMENT, AND PREPARATION METHOD AND USE THEREOFJune 2022June 2025Allow3500NoNo
17838182MULTIPURPOSE DISINFECTION SOLUTIONSJune 2022March 2023Abandon911NoNo
17836261BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITESJune 2022December 2023Allow1820NoNo
17835442ENHANCED DELIVERY EPINEPHRINE COMPOSITIONSJune 2022September 2023Allow1610YesNo
17771643Compositions and Methods for Promoting Plant HealthApril 2022December 2025Abandon4420NoNo
17770393SEQUENTIAL MULTI-STEP FLASH NANOPRECIPITATION FOR THE FORMATION OF NANOPARTICLES WITH HIGH CORE LOADINGSApril 2022August 2025Allow4010YesNo
17769604LIQUID-CRYSTAL POLYESTER POWDER AND METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER SOLUTION COMPOSITIONApril 2022August 2025Abandon4010NoNo
17721452PARTICULATE COMPOSITIONS AND METHODS OF USEApril 2022July 2024Abandon2720NoNo
17768555METHOD FOR SUPPRESSING PRODUCTION OF ASENAPINE-N-OXIDEApril 2022May 2025Allow3710YesNo
17754669ALKENE-CONTAINING AMIDE COMPOUND AND APPLICATION THEREOFApril 2022April 2025Allow3610NoNo
17712516ORAL PHARMACEUTICAL COMPOSITIONApril 2022August 2023Abandon1710NoNo
17764564ARTIFICIAL CARTILAGEMarch 2022January 2026Abandon4520YesNo
17703102GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERYMarch 2022April 2023Allow1330YesNo
17761955PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOFMarch 2022June 2025Abandon3950YesNo
17696822BiocidalMarch 2022October 2023Allow1950YesNo
17696312METHOD OF INDUCING SATIETYMarch 2022August 2023Abandon1710NoNo
17639452STRIGOLACTONE DERIVATIVES AS PLANT GROWTH REGULATOR COMPOUNDSMarch 2022March 2025Abandon3610NoNo
17639397TRACEABLE COMPOSITE FOR MARKING SEEDS AND PLANTSMarch 2022June 2025Abandon4001NoNo
17666685PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITYFebruary 2022April 2023Allow1510YesNo
17628429DETERGENT-FREE DECELLULARIZED EXTRACELLULAR MATRIX PREPARATION METHODS AND BIOINKS FOR 3D PRINTINGJanuary 2022October 2024Allow3300YesNo
17597464BIO-INSPIRED TISSUE-ADHESIVE HYDROGEL PATCH AND USES THEREOFJanuary 2022December 2025Allow4720NoNo
17621014METHOD FOR PRODUCING A BIOCIDEDecember 2021July 2023Allow1820YesNo
17617334LOW-LABOR INTENSITY AND SIMPLE METHOD FOR REDUCING Cd CONTENT OF RICE AND USE THEREOFDecember 2021February 2026Abandon5030NoNo
17617146TOPICAL TIME RELEASE DELIVERY USING LAYERED BIOPOLYMERDecember 2021March 2025Abandon3910NoNo
17543265APPARATUS AND METHOD FOR PROTECTING AGAINST MICROBIAL HAZARDSDecember 2021November 2025Allow4780YesNo
17616401COSMETICDecember 2021October 2025Abandon4720NoNo
17539320THE COMBINED ADMINISTRATION OF A PENETRATION AGENT AND A SULFUR CONTAINING COMPOUND TO PLANTSDecember 2021April 2025Abandon4110NoNo
17510611FUNGICIDAL COMBINATIONSOctober 2021October 2023Abandon2310NoNo
17510554METAL-INFUSED ANTIMICROBIAL MATERIAL AND METHOD OF PREPARATION THEREOFOctober 2021February 2025Allow4040YesNo
17502228SOIL BLENDS CONTAINING AN INSECTICIDE AND METHODS FOR PRODUCTION AND USE THEREOFOctober 2021February 2024Allow2820YesNo
17594317PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDSOctober 2021May 2025Abandon4320NoNo
17598536CARRIER SYSTEM FOR PREPARING HERBACEOUS EXTRACTSSeptember 2021September 2024Allow3620YesNo
17475370GREEN METHOD AND APPLICATION FOR INHIBITING TOXIN-PRODUCING ASPERGILLUS FLAVUSSeptember 2021March 2026Abandon5420NoNo
17469006SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONSSeptember 2021March 2023Allow1810NoNo
17466977Use of Erythritol Compositions As Mammal-Safe InsecticidesSeptember 2021November 2022Abandon1420YesNo
17430921Herbicidal CompositionsAugust 2021December 2024Abandon4010NoNo
17358250Methods and Compositions for Use in Glued-Wood ProductsJune 2021February 2026Abandon5641YesNo
17350746BIOACTIVE POLYPEPTIDES FOR IMPROVEMENTS IN PLANT PROTECTION, GROWTH AND PRODUCTIVITYJune 2021November 2024Allow4110YesNo
17414443R-TYPE PYRIDYLOXYCARBOXYLIC ACID, SALT AND ESTER DERIVATIVE THEREOF, AND PREPARATION METHOD THEREFOR, AND HERBICIDAL COMPOSITION AND APPLICATION THEREOFJune 2021January 2025Allow4320NoNo
17336169COATED SUBSTRATES AND ARTICLES WITH ANTI-VIRAL PROPERTIES, AND FABRICATION PROCESSESJune 2021March 2023Allow2140YesNo
17332954USE OF QUERCETIN IN PLANT AGING PROMOTERMay 2021December 2021Allow710YesNo
17293082HERBICIDAL COMPOUNDSMay 2021July 2024Abandon3810NoNo
17317705NANOSTRUCTURED PRODUCT FOR FACILITATING DEACTIVATING OF MICROORGANISMSMay 2021January 2022Abandon810NoNo
17291142COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND VERY LONG CHAIN FATTY ACID (VLCFA) SYNTHESIS INHIBITOR HERBICIDESMay 2021June 2024Abandon3810NoNo
17290529HARMFUL ORGANISM CONTROL COMPOSITION AND METHOD FOR USING THE SAMEApril 2021December 2024Abandon4420NoNo
17243207Product and Method for Providing Enrichment and Facilitating Expression of Natural Behaviors in PigsApril 2021February 2023Allow2200YesNo
17233873GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERYApril 2021December 2021Allow820YesNo
17232350METHOD AND SYSTEM OF IMPROVING THE PERSONAL PROTECTIVE EQUIPMENT OF HEALTHCARE WORKERS AND THE GENERAL PUBLIC USING ANTIMICROBIAL TECHNOLOGY ADDITIVESApril 2021December 2021Abandon810NoNo
17225232ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITIONApril 2021April 2023Abandon2410NoNo
17214376TOBACCO AXILLARY BUD GROWTH INHIBITORS AND METHODS OF INHIBITING GROWTH OF TOBACCO AXILLARY BUDSMarch 2021March 2026Allow5950YesNo
17278129PREPARATION OF PYRIDAZINYL AMINE COMPOUND AND APPLICATION THEREOFMarch 2021June 2024Abandon3810NoNo
17271358CRYSTALLIZATION INHIBITORS IN AGRICULTURAL FORMULATIONSFebruary 2021October 2024Abandon4410NoNo
17173407WEAKLY ALKALINE PERACETIC ACID SOLUTIONFebruary 2021July 2023Abandon3010NoNo
17267685SHAMPOO COMPOSITION WITH NON-SULFATE SURFACTANT AND COMPLEXATION COMPOUND FORMING A COACERVATEFebruary 2021December 2025Allow5840YesNo
17164293ACTIVE COMPOUND COMBINATIONS COMPRISING A (THIO)CARBOXAMIDE DERIVATIVE AND A FUNGIDICAL COMPOUNDFebruary 2021January 2026Allow6031YesNo
17164434BIOSTIMULANT CONCENTRATE AND METHODS THEREOFFebruary 2021April 2024Allow3820YesNo
17264326COMPOSITION INCLUDING AN ANTIMICROBIAL BOOSTING AGENT INCLUDING A SULTAINE AND METHODS OF INCREASING THE ANTIMICROBIAL EFFECTIVENESS OF A COMPOSITIONJanuary 2021February 2025Allow4951YesNo
17149932Antimicrobial AdhesivesJanuary 2021June 2022Abandon1730YesNo
17257381SPECIAL CONTROLLED-RELEASE BACTERIAL FERTILIZER FOR PEANUTS AND PREPARATION METHOD THEREOFDecember 2020February 2024Allow3710YesNo
17132795ANTIMICROBIAL ELASTOMERIC FORMULATIONDecember 2020June 2023Abandon2910NoNo
16973704NEW USES OF 9-(3-DEOXY-BETA-D-RIBOFURANOSYL)ADENINEDecember 2020January 2024Abandon3710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHLIENTZ, NATHAN W.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
39
Examiner Affirmed
31
(79.5%)
Examiner Reversed
8
(20.5%)
Reversal Percentile
33.9%
Lower than average

What This Means

With a 20.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
130
Allowed After Appeal Filing
27
(20.8%)
Not Allowed After Appeal Filing
103
(79.2%)
Filing Benefit Percentile
27.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SCHLIENTZ, NATHAN W - Prosecution Strategy Guide

Executive Summary

Examiner SCHLIENTZ, NATHAN W works in Art Unit 1616 and has examined 861 patent applications in our dataset. With an allowance rate of 40.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner SCHLIENTZ, NATHAN W's allowance rate of 40.5% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SCHLIENTZ, NATHAN W receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SCHLIENTZ, NATHAN W is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -27.4% benefit to allowance rate for applications examined by SCHLIENTZ, NATHAN W. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.5% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.8% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 48.7% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 37.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.2% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.1% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.